Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies

Advanced Drug Delivery Reviews

Volumn 96, Issue , 2016, Pages 234-244

  Tzatzalos, Evangeline ^a   Abilez, Oscar J ^a   Shukla, Praveen ^a   Wu, Joseph C ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Disease modeling; Drug screening; Induced pluripotent stem cells; Tissue engineering

Indexed keywords

CELL ENGINEERING; CELLS; CYTOLOGY; DIAGNOSIS; HEART; HISTOLOGY; PRECISION ENGINEERING; STEM CELLS; TISSUE;

CARDIO-VASCULAR DISEASE; CARDIOVASCULAR TISSUE ENGINEERING; COMBINED TECHNOLOGY; DISEASE MODELING; DRUG SCREENING; ENGINEERED HEART TISSUES; INDUCED PLURIPOTENT STEM CELLS; MACRO- AND MICROSTRUCTURE;

TISSUE ENGINEERING;

GREPAFLOXACIN; ROFECOXIB; ROSIGLITAZONE; TERFENADINE;

CARDIAC STEM CELL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; DISEASE MODEL; DRUG SCREENING; ELECTROSTIMULATION; EMBRYONIC STEM CELL; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HUMAN; MECHANICAL STIMULATION; NONHUMAN; OXYGEN DIFFUSION; PERSONALIZED MEDICINE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; STROMA CELL; TISSUE ENGINEERING; TRANSLATIONAL RESEARCH; ANIMAL; BIOLOGICAL MODEL; CARDIAC MUSCLE CELL; CARDIOVASCULAR DISEASES; CYTOLOGY; DRUG EFFECTS; HEART; INDUCED PLURIPOTENT STEM CELL; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; DRUG EVALUATION, PRECLINICAL; HEART; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, CARDIOVASCULAR; MYOCYTES, CARDIAC; TISSUE ENGINEERING; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84951784669     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.09.010     Document Type: Review

References (124)

1. Laslett L.J., Alagona P., Clark B.A., Drozda J.P., Saldivar F., Wilson S.R., Poe C., Hart M. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. J. Am. Coll. Cardiol. 2012, 60:S1-S49.
2. Herper M. The cost of creating a new drug now $5 billion, pushing big pharma to change http://www.forbes.com/sites/matthewherper/2013/08/11/how-the-staggering-cost-of-inventing-new-drugs-is-shaping-the-future-of-medicine/.
3. Mathur A., Loskill P., Hong S., Lee J., Marcus S.G., Dumont L., Conklin B.R., Willenbring H., Lee L.P., Healy K.E. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development. Stem Cell Res. Ther. 2013, 4(Suppl. 1):S14.
4. Adams C.P., Brantner V.V. Spending on New Drug Development. Health Economics 2010, 19:130-141.
5. Engle S.J., Puppala D. Integrating human pluripotent stem cells into drug development. Cell Stem Cell 2013, 12:669-677.
6. Munos B.H., Chin W.W. A call for sharing: adapting pharmaceutical research to new realities. Sci. Transl. Med. 2009, 1.
7. Ferri N., Siegl P., Corsini A., Herrmann J., Lerman A., Benghozi R. Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Pharmacol. Ther. 2013, 138:470-484.
8. Hutchinson L., Kirk R. High drug attrition rates-where are we going wrong?. Nat. Rev. Clin. Oncol. 2011, 8:189-190.
9. Mordwinkin N.M., Burridge P.W., Wu J.C. A review of human pluripotent stem cell-derived cardiomyocytes for high-throughput drug discovery, cardiotoxicity screening, and publication standards. J. Cardiovasc. Transl. Res. 2013, 6:22-30.
10. Mandenius C.F., Steel D., Noor F., Meyer T., Heinzle E., Asp J., Arain S., Kraushaar U., Bremer S., Class R., Sartipy P. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review. J. Appl. Toxicol. 2011, 31:191-205.
11. Beqqali A., van Eldik W., Mummery C., Passier R. Human stem cells as a model for cardiac differentiation and disease. Cell. Mol. Life Sci. 2009, 66:800-813.
12. Brandenburger M., Wenzel J., Bogdan R., Richardt D., Nguemo F., Reppel M., Hescheler J., Terlau H., Dendorfer A. Organotypic slice culture from human adult ventricular myocardium. Cardiovasc. Res. 2012, 93:50-59.
13. Matsa E., Burridge P.W., Wu J.C. Human stem cells for modeling heart disease and for drug discovery. Sci. Transl. Med. 2014, 6. (239ps236).
14. Kaese S., Verheule S. Cardiac electrophysiology in mice: a matter of size. Front. Physiol. 2012, 3:345.
15. Lawrence C.L., Pollard C.E., Hammond T.G., Valentin J.P. In vitro models of proarrhythmia. Br. J. Pharmacol. 2008, 154:1516-1522.
16. Liang P., Lan F., Lee A.S., Gong T., Sanchez-Freire V., Wang Y., Diecke S., Sallam K., Knowles J.W., Wang P.J., Nguyen P.K., Bers D.M., Robbins R.C., Wu J.C. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013, 127:1677-1691.
17. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
18. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-676.
19. Burridge P.W., Matsa E., Shukla P., Lin Z.C., Churko J.M., Ebert A.D., Lan F., Diecke S., Huber B., Mordwinkin N.M., Plews J.R., Abilez O.J., Cui B., Gold J.D., Wu J.C. Chemically defined generation of human cardiomyocytes. Nat. Methods 2014, 11:855-860.
20. Lian X., Hsiao C., Wilson G., Zhu K., Hazeltine L.B., Azarin S.M., Raval K.K., Zhang J., Kamp T.J., Palecek S.P. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:E1848-E1857.
21. Carvajal-Vergara X., Sevilla A., D'Souza S.L., Ang Y.S., Schaniel C., Lee D.F., Yang L., Kaplan A.D., Adler E.D., Rozov R., Ge Y., Cohen N., Edelmann L.J., Chang B., Waghray A., Su J., Pardo S., Lichtenbelt K.D., Tartaglia M., Gelb B.D., Lemischka I.R. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010, 465:808-812.
22. Moretti A., Bellin M., Welling A., Jung C.B., Lam J.T., Bott-Flugel L., Dorn T., Goedel A., Hohnke C., Hofmann F., Seyfarth M., Sinnecker D., Schomig A., Laugwitz K.L. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 2010, 363:1397-1409.
23. Itzhaki I., Maizels L., Huber I., Zwi-Dantsis L., Caspi O., Winterstern A., Feldman O., Gepstein A., Arbel G., Hammerman H., Boulos M., Gepstein L. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011, 471:225-229.
24. Sun N., Yazawa M., Liu J., Han L., Sanchez-Freire V., Abilez O.J., Navarrete E.G., Hu S., Wang L., Lee A., Pavlovic A., Lin S., Chen R., Hajjar R.J., Snyder M.P., Dolmetsch R.E., Butte M.J., Ashley E.A., Longaker M.T., Robbins R.C., Wu J.C. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 2012, 4:130-147.
25. Lan F., Lee A.S., Liang P., Sanchez-Freire V., Nguyen P.K., Wang L., Han L., Yen M., Wang Y., Sun N., Abilez O.J., Hu S., Ebert A.D., Navarrete E.G., Simmons C.S., Wheeler M., Pruitt B., Lewis R., Yamaguchi Y., Ashley E.A., Bers D.M., Robbins R.C., Longaker M.T., Wu J.C. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013, 12:101-113.
26. Yazawa M., Hsueh B., Jia X., Pasca A.M., Bernstein J.A., Hallmayer J., Dolmetsch R.E. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011, 471:230-234.
27. Ebert A.D., Kodo K., Liang P., Wu H., Huber B.C., Riegler J., Churko J., Lee J., de Almeida P., Lan F., Diecke S., Burridge P.W., Gold J.D., Mochly-Rosen D., Wu J.C. Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system. Sci. Transl. Med. 2014, 6. (255ra130).
28. Morita H., Wu J., Zipes D.P. The QT syndromes: long and short. Lancet 2008, 372:750-763.
29. Sallam K., Li Y., Sager P.T., Houser S.R., Wu J.C. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. Circ. Res. 2015, 116:1989-2004.
30. Curran M.E., Splawski I., Timothy K.W., Vincen G.M., Green E.D., Keating M.T. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80:795-803.
31. Sun N., Yazawa M., Liu J., Han L., Sanchez-Freire V., Abilez O.J., Navarrete E.G., Hu S., Wang L., Lee A., Pavlovic A., Lin S., Chen R., Hajjar R.J., Snyder M.P., Dolmetsch R.E., Butte M.J., Ashley E.A., Longaker M.T., Robbins R.C., Wu J.C. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 2012, 4. (130ra147).
32. Andersson B., Hamm C., Persson S., Wikstrom G., Sinagra G., Hjalmarson A., Waagstein F. Improved exercise hemodynamic status in dilated cardiomyopathy after beta-adrenergic blockade treatment. J. Am. Coll. Cardiol. 1994, 23:1397-1404.
33. Engelmeier R.S., O'Connell J.B., Walsh R., Rad N., Scanlon P.J., Gunnar R.M. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation 1985, 72:536-546.
34. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., Jessup M., Konstam M.A., Mancini D.M., Michl K., Oates J.A., Rahko P.S., Silver M.A., Stevenson L.W., Yancy C.W., Antman E.M., Smith S.C., Adams C.D., Anderson J.L., Faxon D.P., Fuster V., Halperin J.L., Hiratzka L.F., Jacobs A.K., Nishimura R., Ornato J.P., Page R.L., Riegel B. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005, 112:e154-e235.
35. Wu H., Lee J., Vincent L.G., Wang Q., Gu M., Lan F., Churko J.M., Sallam K.I., Matsa E., Sharma A., Gold J.D., Engler A.J., Xiang Y.K., Bers D.M., Wu J.C. Epigenetic regulation of phosphodiesterases 2A and 3A underlies compromised beta-adrenergic signaling in an iPSC model of dilated cardiomyopathy. Cell Stem Cell 2015, 17:89-100.
36. Matsa E., Rajamohan D., Dick E., Young L., Mellor I., Staniforth A., Denning C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur. Heart J. 2011, 32:952-962.
37. Keung W., Boheler K.R., Li R.A. Developmental cues for the maturation of metabolic, electrophysiological and calcium handling properties of human pluripotent stem cell-derived cardiomyocytes. Stem Cell Res. Ther. 2014, 5. (10.1186).
38. van den Heuvel N.H., van Veen T.A., Lim B., Jonsson M.K. Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes. J. Mol. Cell. Cardiol. 2014, 67:12-25.
39. Yang X., Pabon L., Murry C.E. Engineering adolescence maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Res. 2014, 114:511-523.
40. Mummery C.L., Zhang J., Ng E.S., Elliott D.A., Elefanty A.G., Kamp T.J. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes a methods overview. Circ. Res. 2012, 111:344-358.
41. Burridge P.W., Sharma A., Wu J.C. Genetic and epigenetic regulation of human cardiac reprogramming and differentiation in regenerative medicine. Ann. Rev. Genet. 2015, 49:49:20.1-20.14.
42. Guo L., Abrams R.M., Babiarz J.E., Cohen J.D., Kameoka S., Sanders M.J., Chiao E., Kolaja K.L. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol. Sci. 2011, 123:281-289.
43. Sanchez-Freire V., Lee A.S., Hu S., Abilez O.J., Liang P., Lan F., Huber B.C., Ong S.G., Hong W.X., Huang M., Wu J.C. Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells. J. Am. Coll. Cardiol. 2014, 64:436-448.
44. Ebert A.D., Diecke S., Chen I.Y., Wu J.C. Reprograming and transdifferentiation for cardiovascular development and regenerative medicine: where do we stand?. EMBO Mol. Med. 2015, 7:1090-1103.
45. Hwang H.S., Kryshtal D.O., Feaster T.K., Sanchez-Freire V., Zhang J., Kamp T.J., Hong C.C., Wu J.C., Knollmann B.C. Comparable calcium handling of human iPSC-derived cardiomyocytes generated by multiple laboratories. J. Mol. Cell. Cardiol. 2015, 85:79-88.
46. Novak A., Barad L., Zeevi-Levin N., Shick R., Shtrichman R., Lorber A., Itskovitz-Eldor J., Binah O. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to beta-adrenergic stimulation. J. Cell. Mol. Med. 2012, 16:468-482.
47. Satin J., Kehat I., Caspi O., Huber I., Arbel G., Itzhaki I., Magyar J., Schroder E.A., Perlman I., Gepstein L. Mechanism of spontaneous excitability in human embryonic stem cell derived cardiomyocytes. J. Physiol. 2004, 559:479-496.
48. Burridge P.W., Keller G., Gold J.D., Wu J.C. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. Cell Stem Cell 2012, 10:16-28.
49. Ma J., Guo L., Fiene S.J., Anson B.D., Thomson J.A., Kamp T.J., Kolaja K.L., Swanson B.J., January C.T. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 2011, 301:H2006-H2017.
50. Zhang D., Shadrin I.Y., Lam J., Xian H.Q., Snodgrass H.R., Bursac N. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 2013, 34:5813-5820.
51. Riegler J., Tiburcy M., Ebert A., Tzatzalos E., Raaz U., Abilez O.J., Shen Q., Kooreman N.G., Neofytou E., Chen V.C., Wang M., Meyer T., Tsao P.S., Connolly A.J., Couture L.A., Gold J.D., Zimmerman W.H., Wu J.C. Human engineered heart muscles engraft and survive long term in a rodent myocardial infarction model. Circ. Res. 2015, 117:720-730.
52. Navarrete E.G., Liang P., Lan F., Sanchez-Freire V., Simmons C., Gong T., Sharma A., Burridge P.W., Patlolla B., Lee A.S., Wu H., Beygui R.E., Wu S.M., Robbins R.C., Bers D.M., Wu J.C. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 2013, 128:S3-S13.
53. Burridge P.W., Homström A., Wu J.C. Chemically defined culture and cardiomyocyte differentiation of human pluripotent stem cells. Curr. Protoc. Hum. Genet. 2015, 87:21.3.1-21.3.15.
54. Zhang J., Wilson G.F., Soerens A.G., Koonce C.H., Yu J., Palecek S.P., Thomson J.A., Kamp T.J. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res. 2009, 104:e30-e41.
55. Wang Y., Liang P., Lan F., Wu H., Lisowski L., Gu M., Hu S., Kay M.A., Urnov F.D., Shinnawi R., Gold J.D., Gepstein L., Wu J.C. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J. Am Coll Cardiol. 2014, 64:451-459.
56. Lahti A.L., Kujala V.J., Chapman H., Koivisto A.-P., Pekkanen-Mattila M., Kerkelä E., Hyttinen J., Kontula K., Swan H., Conklin B.R. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Model. Mech. 2012, 5:220-230.
57. Narsinh K.H., Sun N., Sanchez-Freire V., Lee A.S., Almeida P., Hu S., Jan T., Wilson K.D., Leong D., Rosenberg J. Single cell transcriptional profiling reveals heterogeneity of human induced pluripotent stem cells. J. Clin. Invest. 2011, 121:1217.
58. Lieu D.K., Fu J.-D., Chiamvimonvat N., Tung K.W.C., McNerney G.P., Huser T., Keller G., Kong C.-W., Li R.A. Mechanism-based facilitated maturation of human pluripotent stem cell-derived cardiomyocytes. Circ. Arrhythm. Electrophysiol. 2013, (CIRCEP. 112.973420).
59. Fu J.D., Rushing S.N., Lieu D.K., Chan C.W., Kong C.W., Geng L., Wilson K.D., Chiamvimonvat N., Boheler K.R., Wu J.C., Keller G., Hajjar R.J., Li R.A. Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One 2011, 6.
60. Kuppusamy K.T., Jones D.C., Sperber H., Madan A., Fischer K.A., Rodriguez M.L., Pabon L., Zhu W.Z., Tulloch N.L., Yang X., Sniadecki N.J., Laflamme M.A., Ruzzo W.L., Murry C.E., Ruohola-Baker H. Let-7 family of microRNA is required for maturation and adult-like metabolism in stem cell-derived cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E2785-E2794.
61. Karakikes I., Ameen M., Termglinchan V., Wu J.C. Human induced pluripotent stem cell-derived cardiomyocytes: insights into molecular, cellular, and functional phenotypes. Circ. Res. 2015, 117:80-88.
62. Kurokawa Y.K., George S.C. Tissue engineering the cardiac microenvironment: multicellular microphysiological systems for drug screening. Adv. Drug Deliv. Rev. 2016, 96:225-233.
63. Yu J., Vodyanik M.A., Smuga-Otto K., Antosiewicz-Bourget J., Frane J.L., Tian S., Nie J., Jonsdottir G.A., Ruotti V., Stewart R., Slukvin I.I., Thomson J.A. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318:1917-1920.
64. Eschenhagen T., Fink C., Remmers U., Scholz H., Wattchow J., Weil J., Zimmermann W., Dohmen H.H., Schafer H., Bishopric N., Wakatsuki T., Elson E.L. Three-dimensional reconstitution of embryonic cardiomyocytes in a collagen matrix: a new heart muscle model system. FASEB J. 1997, 11:683-694.
65. McDonald T.F., Sachs H.G., DeHaan R.L. Development of sensitivity to tetrodotoxin in beating chick embryo hearts, single cells, and aggregates. Science 1972, 176:1248-1250.
66. Vandenburgh H.H., Karlisch P., Farr L. Maintenance of highly contractile tissue-cultured avian skeletal myotubes in collagen gel. In Vitro Cell. Dev. Biol. 1988, 24:166-174.
67. Zimmermann W.H., Fink C., Kralisch D., Remmers U., Weil J., Eschenhagen T. Three-dimensional engineered heart tissue from neonatal rat cardiac myocytes. Biotechnol. Bioeng. 2000, 68:106-114.
68. Angst B.D., Khan L.U., Severs N.J., Whitely K., Rothery S., Thompson R.P., Magee A.I., Gourdie R.G. Dissociated spatial patterning of gap junctions and cell adhesion junctions during postnatal differentiation of ventricular myocardium. Circ. Res. 1997, 80:88-94.
69. Vaidya D., Tamaddon H.S., Lo C.W., Taffet S.M., Delmar M., Morley G.E., Jalife J. Null mutation of connexin43 causes slow propagation of ventricular activation in the late stages of mouse embryonic development. Circ. Res. 2001, 88:1196-1202.
70. Gutstein D.E., Morley G.E., Tamaddon H., Vaidya D., Schneider M.D., Chen J., Chien K.R., Stuhlmann H., Fishman G.I. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ. Res. 2001, 88:333-339.
71. Zimmerman R.L., Das K.M., Burke M.A., Young N.A., Solomides C.C., Bibbo M. The clinical utility of the Das-1 monoclonal antibody in identifying adenocarcinoma of the colon metastatic to the liver in fine-needle aspiration tissue. Cancer 2002, 96:370-373.
72. Liau B., Christoforou N., Leong K.W., Bursac N. Pluripotent stem cell-derived cardiac tissue patch with advanced structure and function. Biomaterials 2011, 32:9180-9187.
73. Tulloch N.L., Muskheli V., Razumova M.V., Korte F.S., Regnier M., Hauch K.D., Pabon L., Reinecke H., Murry C.E. Growth of engineered human myocardium with mechanical loading and vascular coculture. Circ. Res. 2011, 109:47-59.
74. Zimmermann W.H., Didie M., Wasmeier G.H., Nixdorff U., Hess A., Melnychenko I., Boy O., Neuhuber W.L., Weyand M., Eschenhagen T. Cardiac grafting of engineered heart tissue in syngenic rats. Circulation 2002, 106:I151-I157.
75. Evans C.L., Hill A.V. The relation of length to tension development and heat production on contraction in muscle. J. Physiol. 1914, 49:10-16.
76. Knowlton F.P., Starling E.H. The influence of variations in temperature and blood-pressure on the performance of the isolated mammalian heart. J. Physiol. 1912, 44:206-219.
77. Roy C.S. On the influences which modify the work of the heart. J. Physiol. 1879, 1. (452-496 458).
78. Katz A.M. Ernest Henry Starling, his predecessors, and the "Law of the Heart". Circulation 2002, 106:2986-2992.
79. Eschenhagen T., Didie M., Munzel F., Schubert P., Schneiderbanger K., Zimmermann W.H. 3D engineered heart tissue for replacement therapy. Basic Res. Cardiol. 2002, 97(Suppl. 1):I146-I152.
80. Zimmermann W.H., Schneiderbanger K., Schubert P., Didie M., Munzel F., Heubach J.F., Kostin S., Neuhuber W.L., Eschenhagen T. Tissue engineering of a differentiated cardiac muscle construct. Circ. Res. 2002, 90:223-230.
81. Fung Y.-c. A First Course in Continuum Mechanics 1977, Prentice-Hall, Inc., Englewood Cliffs, NJ, (351 p., 1 (1977)).
82. Zimmermann W.H., Melnychenko I., Eschenhagen T. Engineered heart tissue for regeneration of diseased hearts. Biomaterials 2004, 25:1639-1647.
83. Hibberd M.G., Jewell B.R. Calcium- and length-dependent force production in rat ventricular muscle. J. Physiol. 1982, 329:527-540.
84. Zimmermann W.H., Melnychenko I., Wasmeier G., Didie M., Naito H., Nixdorff U., Hess A., Budinsky L., Brune K., Michaelis B., Dhein S., Schwoerer A., Ehmke H., Eschenhagen T. Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts. Nat. Med. 2006, 12:452-458.
85. Radisic M., Park H., Shing H., Consi T., Schoen F.J., Langer R., Freed L.E., Vunjak-Novakovic G. Functional assembly of engineered myocardium by electrical stimulation of cardiac myocytes cultured on scaffolds. Proc. Natl. Acad. Sci. 2004, 101:18129-18134.
86. Solaro R.J. Mechanisms of the Frank-Starling law of the heart: the beat goes on. Biophys. J. 2007, 93:4095-4096.
87. Holubarsch C., Ruf T., Goldstein D.J., Ashton R.C., Nickl W., Pieske B., Pioch K., Ludemann J., Wiesner S., Hasenfuss G., Posival H., Just H., Burkhoff D. Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels. Circulation 1996, 94:683-689.
88. Serena E., Figallo E., Tandon N., Cannizzaro C., Gerecht S., Elvassore N., Vunjak-Novakovic G. Electrical stimulation of human embryonic stem cells: cardiac differentiation and the generation of reactive oxygen species. Exp. Cell Res. 2009, 315:3611-3619.
89. Chiu L.L., Iyer R.K., King J.P., Radisic M. Biphasic electrical field stimulation aids in tissue engineering of multicell-type cardiac organoids. Tissue Eng. Part A 2011, 17:1465-1477.
90. Nunes S.S., Miklas J.W., Liu J., Aschar-Sobbi R., Xiao Y., Zhang B., Jiang J., Masse S., Gagliardi M., Hsieh A., Thavandiran N., Laflamme M.A., Nanthakumar K., Gross G.J., Backx P.H., Keller G., Radisic M. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat. Methods 2013, 10:781-787.
91. Deisseroth K. Optogenetics. Nat. Methods 2011, 8:26-29.
92. Abilez O.J., Wong J., Prakash R., Deisseroth K., Zarins C.K., Kuhl E. Multiscale computational models for optogenetic control of cardiac function. Biophys. J. 2011, 101:1326-1334.
93. Abilez O.J. Cardiac optogenetics. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2011, 2012:1386-1389.
94. Matsuno-Yagi A., Mukohata Y. Two possible roles of bacteriorhodopsin; a comparative study of strains of Halobacterium halobium differing in pigmentation. Biochem. Biophys. Res. Commun. 1977, 78:237-243.
95. Weiss T.F. Cellular Biophysics, 2v.: Transport and Electrical Properties 1996, MIT Press.
96. Trautwein W., Kassebaum D.G., Nelson R.M., Hecht H.H. Electrophysiological study of human heart muscle. Circ. Res. 1962, 10:306-312.
97. S. Schaaf, A. Shibamiya, M. Mewe, A. Eder, A. Stohr, M.N. Hirt, T. Rau, W.H. Zimmermann, L. Conradi, T. Eschenhagen, A. Hansen, Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology, PLoS One, 6 e26397.
98. Hoekstra M., Mummery C.L., Wilde A.A., Bezzina C.R., Verkerk A.O. Induced pluripotent stem cell derived cardiomyocytes as models for cardiac arrhythmias. Front. Physiol. 2012, 3:346.
99. Bursac N., Papadaki M., Cohen R.J., Schoen F.J., Eisenberg S.R., Carrier R., Vunjak-Novakovic G., Freed L.E. Cardiac muscle tissue engineering: toward an in vitro model for electrophysiological studies. Am. J. Physiol. 1999, 277:H433-H444.
100. Boudou T., Legant W.R., Mu A., Borochin M.A., Thavandiran N., Radisic M., Zandstra P.W., Epstein J.A., Margulies K.B., Chen C.S. A microfabricated platform to measure and manipulate the mechanics of engineered cardiac microtissues. Tissue Eng. Part A 2012, 18:910-919.
101. Iyer R.K., Chui J., Radisic M. Spatiotemporal tracking of cells in tissue-engineered cardiac organoids. J. Tissue Eng. Regen. Med. 2009, 3:196-207.
102. Gillis A.M., Fast V.G., Rohr S., Kleber A.G. The role of tissue geometry in the changes in transmembrane potential in patterned myocyte cultures. Circulation 2000, 101:2438-2445.
103. Efimov I.R., Nikolski V.P., Salama G. Optical imaging of the heart. Circ. Res. 2004, 95:21-33.
104. Liau B., Zhang D., Bursac N. Functional cardiac tissue engineering. Regen. Med. 2012, 7:187-206.
105. Durrer D., van Dam R.T., Freud G.E., Janse M.J., Meijler F.L., Arzbaecher R.C. Total excitation of the isolated human heart. Circulation 1970, 41:899-912.
106. Stevens K.R., Kreutziger K.L., Dupras S.K., Korte F.S., Regnier M., Muskheli V., Nourse M.B., Bendixen K., Reinecke H., Murry C.E. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:16568-16573.
107. Xiong Q., Hill K.L., Li Q., Suntharalingam P., Mansoor A., Wang X., Jameel M.N., Zhang P., Swingen C., Kaufman D.S. A fibrin patch based enhanced delivery of human embryonic stem cell-derived vascular cell transplantation in a porcine model of postinfarction left ventricular remodeling. Stem Cells 2011, 29:367-375.
108. Riegler J., Gillich A., Shen Q., Gold J.D., Wu J.C. Cardiac tissue slice transplantation as a model to assess tissue-engineered graft thickness, survival, and function. Circulation 2014, 130:S77-S86.
109. Ye L., Chang Y.H., Xiong Q., Zhang P., Zhang L., Somasundaram P., Lepley M., Swingen C., Su L., Wendel J.S., Guo J., Jang A., Rosenbush D., Greder L., Dutton J.R., Zhang J., Kamp T.J., Kaufman D.S., Ge Y. Cardiac repair in a porcine model of acute myocardial infarction with human induced pluripotent stem cell-derived cardiovascular cells. Cell Stem Cell 2014, 15:750-761.
110. Chong J.J., Yang X., Don C.W., Minami E., Liu Y.W., Weyers J.J., Mahoney W.M., Van Biber B., Cook S.M., Palpant N.J., Gantz J.A., Fugate J.A., Muskheli V., Gough G.M., Vogel K.W., Astley C.A., Hotchkiss C.E., Baldessari A., Pabon L., Reinecke H., Gill E.A., Nelson V., Kiem H.P., Laflamme M.A., Murry C.E. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014, 510:273-277.
111. Lee A.S., Xu D., Plews J.R., Nguyen P.K., Nag D., Lyons J.K., Han L., Hu S., Lan F., Liu J., Huang M., Narsinh K.H., Long C.T., de Almeida P.E., Levi B., Kooreman N., Bangs C., Pacharinsak C., Ikeno F., Yeung A.C., Gambhir S.S., Robbins R.C., Longaker M.T., Wu J.C. Preclinical derivation and imaging of autologously transplanted canine induced pluripotent stem cells. J. Biol. Chem. 2011, 286:32697-32704.
112. Nguyen P.K., Riegler J., Wu J.C. Stem cell imaging: from bench to bedside. Cell Stem Cell 2014, 14:431-444.
113. Laflamme M.A., Chen K.Y., Naumova A.V., Muskheli V., Fugate J.A., Dupras S.K., Reinecke H., Xu C., Hassanipour M., Police S., O'Sullivan C., Collins L., Chen Y., Minami E., Gill E.A., Ueno S., Yuan C., Gold J., Murry C.E. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat. Biotechnol. 2007, 25:1015-1024.
114. Transplantation of Human Embryonic Stem Cell-derived Progenitors in Severe Heart Failure (ESCORT) (Last updated: March 31, 2015). https://clinicaltrials.gov/ct2/show/NCT02057900.
115. Carrier R.L., Papadaki M., Rupnick M., Schoen F.J., Bursac N., Langer R., Freed L.E., Vunjak-Novakovic G. Cardiac tissue engineering: cell seeding, cultivation parameters, and tissue construct characterization. Biotechnol. Bioeng. 1999, 64:580-589.
116. Radisic M., Malda J., Epping E., Geng W., Langer R., Vunjak-Novakovic G. Oxygen gradients correlate with cell density and cell viability in engineered cardiac tissue. Biotechnol. Bioeng. 2006, 93:332-343.
117. Carrier R.L., Rupnick M., Langer R., Schoen F.J., Freed L.E., Vunjak-Novakovic G. Effects of oxygen on engineered cardiac muscle. Biotechnol. Bioeng. 2002, 78:617-625.
118. Radisic M., Euloth M., Yang L., Langer R., Freed L.E., Vunjak-Novakovic G. High density seeding of myocyte cells for cardiac tissue engineering. Biotechnol. Bioeng. 2003, 82:403-414.
119. Grosberg A., Alford P.W., McCain M.L., Parker K.K. Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. Lab Chip 2011, 11:4165-4173.
120. Hinson J.T., Chopra A., Nafissi N., Polacheck W.J., Benson C.C., Swist S., Gorham J., Yang L., Schafer S., Sheng C.C., Haghighi A., Homsy J., Hubner N., Church G., Cook S.A., Linke W.A., Chen C.S., Seidman J.G., Seidman C.E. HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy. Science 2015, 349:982-986.
121. Wang G., McCain M.L., Yang L., He A., Pasqualini F.S., Agarwal A., Yuan H., Jiang D., Zhang D., Zangi L., Geva J., Roberts A.E., Ma Q., Ding J., Chen J., Wang D.Z., Li K., Wang J., Wanders R.J., Kulik W., Vaz F.M., Laflamme M.A., Murry C.E., Chien K.R., Kelley R.I., Church G.M., Parker K.K., Pu W.T. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 2014, 20:616-623.
122. Mathur A., Loskill P., Shao K., Huebsch N., Hong S.G., Marcus S.G., Marks N., Mandegar M., Conklin B.R., Lee L.P., Healy K.E. Human iPSC-based cardiac microphysiological system for drug screening applications. Scientific Reports 2015, 5:1-7.
123. Ghista D.N., Sandler H., Vayo W.H. Elastic modulus of the human intact left ventricle-determination and physiological interpretation. Med. Biol. Eng. 1975, 13:151-161.
124. Sheehy S.P., Pasqualini F., Grosberg A., Park S.J., Aratyn-Schaus Y., Parker K.K. Quality metrics for stem cell-derived cardiac myocytes. Stem Cell Rep. 2014, 2:282-294.